Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Open Access
- 31 March 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (3), 245-255
- https://doi.org/10.1016/s1470-2045(10)70295-3
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK, Queen Mary University of London, the Orchid Appeal, National Institutes of Health (SPORE CA92629)
This publication has 42 references indexed in Scilit:
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009
- Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group studyBritish Journal of Cancer, 2009
- Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancerCancer, 2009
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- Cell cycle correlated genes dictate the prognostic power of breast cancer gene listsBMC Medical Genomics, 2008
- Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intentCancer, 2007
- Long-term outcome among men with conservatively treated localised prostate cancerBritish Journal of Cancer, 2006
- Concordance among Gene-Expression–Based Predictors for Breast CancerThe New England Journal of Medicine, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002